Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.

ABSTRACT:

Background

Prior studies evaluating risk for severe urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have reported conflicting findings.

Objective

To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 receptor (GLP-1) agonists.

Design

Population-based cohort study.

Setting

2 large, U.S.-based databases of commercial claims (March 2013 to September 2015).

Participants

Within each database, 2 cohorts were created and matched 1:1 on propensity score. Patients were aged 18 years or older, had type 2 diabetes mellitus, and were initiating use of SGLT-2 inhibitors

SUBMITTER: Dave CV 

PROVIDER: S-EPMC6989379 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature